We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.

Delisted

ICPT was delisted on the 7th of November, 2023.

169 hedge funds and large institutions have $2.42B invested in Intercept Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 74 increasing their positions, 39 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 39

7% less funds holding

Funds holding: 181169 (-12)

20% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 49

21% less capital invested

Capital invested by funds: $3.05B → $2.42B (-$632M)

42% less call options, than puts

Call options by funds: $56.6M | Put options by funds: $96.8M

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

Holders
169
Holders Change
-12
Holders Change %
-6.63%
% of All Funds
4.51%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
39
Increased
74
Reduced
39
Closed
49
Calls
$56.6M
Puts
$96.8M
Net Calls
-$40.2M
Net Calls Change
+$29.3M
Name Holding Trade Value Shares
Change
Change in
Stake
RFC
26
Russell Frank Company
Washington
$15.7M +$3.84M +20,794 +26%
CCI
27
Columbus Circle Investors
$14.5M -$11.2M -60,678 -39%
Massachusetts Financial Services
28
Massachusetts Financial Services
Massachusetts
$13.4M +$15.9M +86,212 New
Ameriprise
29
Ameriprise
Minnesota
$12.2M -$2.32M -12,554 -14%
Bank of America
30
Bank of America
North Carolina
$11.9M -$1.42M -7,715 -9%
SCM
31
Suffolk Capital Management
New York
$11.8M +$2.42M +13,078 +21%
CA
32
Commerzbank Aktiengesellschaft
Germany
$10.8M +$1.86M +10,055 +17%
EA
33
Emerald Advisers
Pennsylvania
$10.5M +$10.9M +59,238 +724%
Geode Capital Management
34
Geode Capital Management
Massachusetts
$10.1M +$384K +2,077 +3%
SAM
35
Senzar Asset Management
New York
$9.66M +$11.4M +61,900 New
Axa
36
Axa
France
$9.46M +$9.35M +50,645 +506%
DM
37
Deerfield Management
New York
$9.42M -$7.07M -38,300 -39%
CS
38
Credit Suisse
Switzerland
$8.75M +$3.23M +17,488 +45%
JP Morgan Chase
39
JP Morgan Chase
New York
$8.55M +$7.25M +39,245 +252%
Goldman Sachs
40
Goldman Sachs
New York
$8.31M +$4.4M +23,804 +81%
GC
41
Guggenheim Capital
Illinois
$7.92M +$3.93M +21,272 +72%
Northern Trust
42
Northern Trust
Illinois
$7.36M -$144K -781 -2%
Deutsche Bank
43
Deutsche Bank
Germany
$7.3M +$5.34M +28,915 +161%
Barclays
44
Barclays
United Kingdom
$7.19M +$6.57M +35,594 +339%
Bank of New York Mellon
45
Bank of New York Mellon
New York
$6.94M -$15.5M -83,906 -65%
RIM
46
Rainier Investment Management
Washington
$6.82M +$8.08M +43,740 New
Allianz Asset Management
47
Allianz Asset Management
Germany
$6.69M +$2.59M +14,025 +49%
EMFAT
48
Emerald Mutual Fund Advisers Trust
Pennsylvania
$6.28M +$7.43M +40,227 New
SO
49
STRS Ohio
Ohio
$6.24M +$7.39M +40,000 New
SDIC
50
South Dakota Investment Council
South Dakota
$6.16M +$7.3M +39,500 New

ICPT Hedge Fund Activity: Q4 2014 in Review

169 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q4 2014, worth a combined $2.42B — down 21% from $3.05B a quarter earlier.

Sellers outnumbered buyers: 49 funds closed out of ICPT and 39 opened new positions — a net loss of 10 holders — while 39 trimmed existing stakes and 74 added.

The largest buyer was First Trust Advisors, adding an estimated $49.1M. The largest seller was Capital World Investors, cutting an estimated $43.2M.

  • 169 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q4 2014, down from 181 in Q3 2014.
  • Funds reported $2.42B of Intercept Pharmaceuticals, Inc. stock for Q4 2014, down 21% quarter-over-quarter.
  • 39 funds opened new Intercept Pharmaceuticals, Inc. positions in Q4 2014 and 49 closed out, a net change of -10 holders.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q4 2014 was First Trust Advisors, an estimated $49.1M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q4 2014 was Capital World Investors, an estimated $43.2M sold.

Based on aggregated 13F filings for Q4 2014.